Lymphoma Patients Respond to Pembrolizumab After Other Therapies Fail, Small Study Indicates
News
Patients with NK-cell or T-cell lymphomas whose previous treatments failed showed remarkably good responses to the immunotherapy Keytruda (pembrolizumab) in a small trial. The study, “PD1 blockade with pembrolizumab is ... Read more